Physician profile
Robert J Maro
NPI 1346284213
$11,679.04
in general payments reported to CMS, 2019-2025
57 companies · $1,837 in 2025
The $1,837 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,393 · 2020: $985 · 2021: $1,798 · 2022: $2,050 · 2023: $1,673 · 2024: $1,944 · 2025: $1,837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,453.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,227.45 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $772.69 | 2019-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $764.18 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Abbott Laboratories | $571.78 | 2019-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $555.80 | 2019-2024 | Myrbetriq, Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $548.18 | 2022-2025 | |
| Glaxosmithkline, LLC. | $496.80 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $437.07 | 2022-2025 | Rexulti |
| Pfizer INC. | $425.74 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $423.85 | 2019-2023 | Xarelto |
| Abbvie INC. | $391.79 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $377.60 | 2019-2024 | Livalo, Seglentis |
| Lilly USA, LLC | $311.89 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Amarin Pharma, INC. | $286.60 | 2019-2020 | |
| Exact Sciences Corporation | $279.21 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Maro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.